TABLE IV.
Vaccine-triggered anaphylaxis cases: demographic and clinical characteristics
| No. of cases (n = 33) | Percent | |
|---|---|---|
| Year | ||
|
| ||
| 2009 | 11 | 33 |
|
| ||
| 2010 | 8 | 24 |
|
| ||
| 2011 | 14 | 42 |
|
| ||
| Setting | ||
|
| ||
| ED | 13 | 39 |
|
| ||
| OPD | 20 | 61 |
|
| ||
| Age group (y) | ||
|
| ||
| 0-17 | 18 | 55 |
|
| ||
| 18-49 | 9 | 27 |
|
| ||
| ≥50 | 6 | 18 |
|
| ||
| Sex | ||
|
| ||
| Female | 20 | 61 |
|
| ||
| Race | ||
|
| ||
| White | 24 | 73 |
|
| ||
| Black | 2 | 6 |
|
| ||
| Unknown | 7 | 21 |
|
| ||
| Past history | ||
|
| ||
| Atopy | 28 | 85 |
|
| ||
| Anaphylaxis* | 3 | 9 |
|
| ||
| Time to onset | ||
|
| ||
| <30 min | 8 | 24 |
|
| ||
| 30 to <120 min | 8 | 24 |
|
| ||
| 2 to <4 h | 10 | 30 |
|
| ||
| 4 to 20 h | 3 | 10 |
|
| ||
| Not documented | 4 | 12 |
|
| ||
| Treatment of episode | ||
|
| ||
| Epinephrine | 15† | 45 |
|
| ||
| Antihistamine | 28 | 85 |
|
| ||
| Corticosteroid | 17 | 52 |
|
| ||
| H2-blocker | 7 | 21 |
|
| ||
| Bronchodilator | 13 | 39 |
|
| ||
| Oxygen | 5 | 15 |
|
| ||
| Intravenous therapy | 5 | 15 |
|
| ||
| Outcome | ||
|
| ||
| Recovered | 33 | 100 |
|
| ||
| Follow-up care | ||
|
| ||
| Inpatient | 1 | 3 |
|
| ||
| Epinephrine autoinjector prescribed | 3 | 9 |
|
| ||
| Referred to allergist | 5 | 15 |
*
Two patients after TIV and 1 patient after aspirin.
†
Brighton Level 1=6, 50%; Brighton Level 2 = 9, 43%.